ArticleTranslational gastroenterology and hepatology2025

Dosing matters: DESTINY-CRC02 and the evolving treatment paradigm for HER2 positive colorectal cancer.

Lindsay M Hannan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.